The current Ebola outbreak in the Democratic Republic of the Congo is now the most severe in the country's recorded history and ranks the third worst on the African continent.
At least 326 people have reported symptoms of hemorrhagic fever in the Central African nation's eastern provinces of North Kivu and Ituri, which share borders with Uganda and Rwanda. Among those cases, 291 have tested positive for Ebola virus disease, according to a daily bulletin from the country's health ministry on Saturday.
There have been 201 deaths thus far, including 166 people who died from confirmed cases of Ebola. The other deaths are from probable cases of Ebola.
"No other epidemic in the world has been as complex as the one we are currently experiencing," the country's health minister, Dr. Oly Ilunga Kalenga, said in a statement late on Friday.
The total number of cases exceed that of the country's first Ebola outbreak, which was recorded in 1976 in the small northern village of Yambuku in what was then Zaire. The ongoing outbreak is also the third most severe in the recorded history of the African continent, following 28,652 cases in the 2013-2016 outbreak in multiple West African nations and 425 cases in the 2000 outbreak in Uganda, according to data from the U.S. Centers for Disease Control and Prevention.
The development comes just a month after the World Health Organization (WHO) concluded the current outbreak does not yet meet the criteria for an international public health emergency — a proclamation that would have mobilized more resources and garnered global attention.
Here is what you need to know about the deadly virus.
The Ebola virus is described as a group of viruses that cause a deadly kind of hemorrhagic fever. The term "hemorrhagic fever" means it causes bleeding inside and outside the body.
The virus has a long incubation period of approximately eight to 21 days. Early symptoms include fever, muscle weakness, sore throat and headaches.
As the disease progresses, the virus can impair kidney and liver function and lead to external and internal bleeding. Its one of the most deadly viruses on Earth with a fatality rate that can reach between approximately 50 to 90 percent. There is no cure.
The WHO has received approval to administer an experimental Ebola vaccine, using a "ring vaccination" approach, around the epicenter of the current outbreak in the Democratic Republic of the Congo. Some 28,000 people, including children as well as health and frontline workers, have been vaccinated in the outbreak zone since Aug. 8, according to the WHO.
The vaccine, which was developed by American pharmaceutical company Merck, has proved effective against the country's previous outbreak in the western province of Equateur.
The virus is transmitted through contact with blood or secretions from an infected person, either directly or through contaminated surfaces, needles or medical equipment. A patient is not contagious until he or she starts showing signs of the disease.
Thankfully, the virus is not airborne, which means a person cannot get the disease simply by breathing the same air as an infected patient.
In this current outbreak, people have been infected in North Kivu and Ituri, which are among the most populous provinces in the Democratic Republic of the Congo and share borders with Uganda and Rwanda.
Those two provinces are awash with conflict and insecurity, particularly in the mineral-rich borderlands where militia activity has surged in the past year, all of which complicates the response to the outbreak. There is also community mistrust, partly due to the security situation, and some residents delay seeking care or avoid follow-up.
Ebola is endemic to the region. This outbreak is the 10th in the Democratic Republic of the Congo since 1976, the year that scientists first identified the deadly virus in Yambuku near the eponymous Ebola River.
This outbreak in the country's eastern region was announced Aug. 1, just days after another outbreak in the western part of the country that killed 33 people (including 17 who had confirmed cases of Ebola) was declared over.
The dangerous virus gets its name from the Ebola River in northern Democratic Republic of the Congo, which was near the site of one of the first outbreaks. The virus was first reported in 1976 in two almost simultaneous outbreaks in the Sudan and the Democratic Republic of the Congo. The outbreaks killed 151 and 280 people, respectively.
Certain bats living in tropical African forests are thought to be the natural hosts of the disease. The initial transmission of an outbreak usually results from a wild animal infecting a human, according to the WHO. Once the disease infects a person, it is easily transmissible between people in close contact.
An outbreak that began in the West African nation of Guinea in March 2014, and soon spread to neighboring Liberia and Sierra Leone, was the largest in history, infecting 28,646 people and causing 11,308 deaths. The outbreak, which the WHO deemed a public health emergency of international concern, was declared over in June 2016.
The virus is not airborne, which means those in close contact can be infected and are most at risk. A person sitting next to an infected person, even if they are contagious, is not extremely likely to be infected.
However, health workers and caregivers of the sick are particularly at risk because they work in close contact with infected patients during the final stages of the disease, when the virus can cause internal and external bleeding.
In the current outbreak alone, 28 health workers have been infected so far and at least three of them have died, according to the WHO.
The organization helping to bring new drugs for rare diseases to market
A research team has reason to celebrate after the Food and Drug Administration granted it approval o..
A research team has reason to celebrate after the Food and Drug Administration granted it approval on Friday to begin a clinical trial for a new pediatric brain cancer drug, one that might have ended up overlooked by pharmaceutical companies.
The lead researcher on the team, Dr. Teresa Purzner has already beat impossible odds. The neurosurgeon and mom of three managed to get the approval in record time and with little money thanks to the help of a team of scientific altruists called SPARK.
The development of new medications in the United States is driven by pharmaceutical companies; researchers at universities rarely bring their discoveries to the bedside. For every 10,000 potential new medicines sitting on laboratory shelves around the country, only one will ever reach patients in need, according to the National Institutes of Health. Why? Because the process can take 10 to 15 years, costing upwards of a billion dollars per drug.
As a result, the number of new medications approved by the FDA has remained stagnant at about 31 per year over the past 10 years. The majority of these medications are similar to already existing ones, and many target diseases for which there are large markets — like hypertension and high cholesterol — and therefore, a return on investment.
Enter SPARK, a non-profit program created in partnership between Stanford University and volunteers from the biotechnology, pharmaceutical, and investment industries, which helps academic researchers bring their discoveries to patients. Since its founding, SPARK has given special consideration to projects typically neglected by pharmaceutical companies, including rare diseases and diseases affecting children.
Purzner put her neurosurgery practice on pause to study medulloblastoma, a type of childhood brain cancer. Compared to diseases like hypertension and high cholesterol, which affect millions of Americans, medulloblastoma is rare, affecting only 250 to 500 children every year.
“Theres something especially poignant about seeing children —beautiful, wonderful, innocent things — and seeing the impact of the therapies we are giving them. The medications, the radiation therapies impact their cognition, their quality of life and their ability to function as independent adults in the future,” Purzner said in an interview with ABC News.
Purzner had a clear goal: to find a targeted therapy that could shut down the basic biochemical pathway responsible for the development of this cancer, and she did. She tested the potential drug in mice with good results, and she just received FDA approval to test it in clinical trials, which she will do through the Pediatric Brain Tumor Consortium. She did it all in five years and for a price tag of $500,000.
“To get from my initial findings in the lab to the point where the Pediatric Brain Tumor Consortium picked it up for clinical trials would have never happened without the help of SPARK… they gave me a clear pathway and made me believe it was possible,” said Purzner.
Every year, SPARK provides 10 teams with funding and expert mentorship to promote efficient and cost-effective drug development. (more…)
Widowed father works with congresswoman on legislation to prevent maternal deaths
Sitting in the hospital room, mother and newborn baby were sound asleep.
“I was overjoyed. I reme..
Sitting in the hospital room, mother and newborn baby were sound asleep.
"I was overjoyed. I remember thinking my family is complete," Charles Johnson told ABC News.
But then he looked down and saw his wife Kiras catheter turn pink and then red with blood.
April 12, 2016 was supposed to be a joyous day for the Johnson family, but it turned into a "nightmare."
Ten hours later, Kira Johnson died as a result of internal bleeding following a cesarean section.
Now, two years later, Johnson is raising two children on his own and advocating to rectify the country's maternal health policies and regulations to prevent anyone else from sharing the same tragedy. Johnson took to Capitol Hill to share his wife's story before members of Congress, working alongside a congresswoman who experienced her own personal difficulties during pregnancy.
Charles and Kira Johnson welcomed their first son Charles V. in 2014. He was delivered via C-section. Two years later, the Johnson family relocated from Atlanta to Los Angeles and learned they were expecting their second baby boy.
"Kira and I had always wanted two boys," Johnson said. "I was excited."
The Johnsons decided to have Langston delivered at Cedars Sinai medical center, a non-profit hospital that is currently ranked as the eighth best hospital in the country by U.S. News and World Report.
Charles Johnson said his wife was in exceptional health and that she took all the necessary prenatal measures to ensure their second child would be born healthy. Since their first son was born via C-section, the doctor suggested the same for their second. (more…)
States look to breathalyze convicted drunk drivers to reduce fatalities
This story is from Kaiser Health News
On Jan. 1, California joined the majority of states that ha..
This story is from Kaiser Health News
On Jan. 1, California joined the majority of states that have laws requiring drivers with drunken-driving convictions to install breathalyzers in vehicles they own or operate.
Researchers, public health advocates and political leaders believe these laws are helping reduce alcohol-related road deaths.
The gadgets, known as ignition interlock devices, are mounted on the steering wheel of a vehicle and prevent it from starting if the drivers blood-alcohol reading is above a predetermined level.
In California, the breathalyzers are mandatory only for repeat offenders. Five other states — Georgia, Indiana, Massachusetts, Montana and Ohio — have similar laws. Thirty-two states and D.C. require the devices even for first-time offenders.
The advent of such laws across the United States in the past 15 years has been accompanied by some good news: Deaths involving drunken driving are only about half of what they were in the early 1980s, though they have ticked back up in recent years. The long-term decline is largely attributable to greater public awareness, stricter seat belt enforcement and the establishment in 2000 of a nationwide legal blood-alcohol threshold of 0.08 percent — far below the 0.15 percent standard commonly used before then.
State Sen. Jerry Hill (D-San Mateo), the author of the California law, said breathalyzers in cars will make roads safer than under the current law, which generally relies on license restrictions and suspensions.
“Weve seen people on a suspended license continue to drive and continue to cause destruction,” said Hill, who lost his best friend to drunken driving in the 1980s.
There is some evidence that the breathalyzers have an impact. Nationally, from 2006 to 2016, ignition-locking breathalyzers prevented 2.3 million attempts to drive by people with a blood-alcohol level at or above 0.08 percent — the legal threshold for driving under the influence — according to a 2017 report by the advocacy group Mothers Against Drunk Driving.
Emma McGinty, an associate professor at the Johns Hopkins Bloomberg School of Public Health, found that laws requiring interlocks for all DUI offenders were associated with a 7 percent drop in the rate of fatal crashes caused by drunken drivers. Another study found that laws covering all offenders were associated with 15 percent fewer alcohol-related fatalities compared with states that have less stringent laws. (more…)
Australia8 months ago
Here’s what’s on the horizon for a male contraceptive pill
Australia6 months ago
Health Minister calls for review of ‘offensive’ Instagram campaign
fun10 months ago
Ashley Graham rocks as she models latest swim range during hot Miami photoshoot
fun10 months ago
Janna Breslin Stuns The Internet In Blue Bikini
Films1 year ago
Maria Contreras-Sweet Bid Leads Weinstein Co Auction; Staff Would Stay, Bob Weinstein Exit, Women Lead Board
Australia3 months ago
Sending Turnbull to Bali conference is in ‘national interest’, Morrison says
Health9 months ago
Cataract Surgery on Ebola Survivors Safe for Docs
fun10 months ago
Is this the cutest picture of Stormi yet? Kylie Jenner gives fans adorable glimpse of sleeping daughter